Attached files

file filename
EX-10.249 - SUPPLEMENTAL INDENTURE 2025 NOTES - Endo International plcex10249endosupplementalind.htm
EX-10.239 - PURCHASE AGREEMENT - Endo International plcex10239purchaseagreementfo.htm
EX-10.244 - SUPPLEMENTAL INDENTURE 2022 NOTES - Endo International plcex10244endosupplementalind.htm
EX-10.243 - RRA 2020 NOTES - Endo International plcex10243endorracounterpartr.htm
EX-10.246 - SUPPLEMENTAL INDENTURE 5.75% 2022 NOTES - Endo International plcex10246endo_supplementalxi.htm
EX-10.248 - RRA 2023 NOTES - Endo International plcex10248endorracounterpartr.htm
EX-10.242 - SUPPLEMENTAL INDENTURE 2020 NOTES - Endo International plcex10242endosupplementalind.htm
EX-10.240 - SUPPLEMENTAL INDENTURE 2019 NOTES - Endo International plcex10240endosupplementalind.htm
EX-10.250 - RRA 2025 NOTES - Endo International plcex10250endorracounterpartr.htm
EX-10.245 - RRA 2022 NOTES - Endo International plcex10245endorracounterpartr.htm
EX-10.241 - RRA 2019 NOTES - Endo International plcex10241endorracounterpartr.htm
EXCEL - IDEA: XBRL DOCUMENT - Endo International plcFinancial_Report.xls
EX-31.1 - CEO SECTION 302 CERTIFICATION - Endo International plcex3113312015ceo302cert.htm
EX-31.2 - CFO SECTION 302 CERTIFICATION - Endo International plcex3123312015cfo302cert.htm
EX-21 - SUBSIDIARIES - Endo International plcex213312015subsidiaries.htm
10-Q - 10-Q - Endo International plcendp-3312015x10q.htm
EX-32.1 - CEO SECTION 906 CERTIFICATION - Endo International plcex3213312015ceo906cert.htm
EX-10.247 - SUPPLEMENTAL INDENTURE 2023 NOTES - Endo International plcex10247endosupplementalind.htm
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Suketu P. Upadhyay, as Chief Financial Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2015 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
 
/S/ SUKETU P. UPADHYAY
Name:
 
Suketu P. Upadhyay
Title:
 
Executive Vice President, Chief Financial Officer
(Principal Financial Officer)
Date: May 11, 2015
A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.